1 Department of Gastrointestinal Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
2 Center of Physical Examination, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819825845. doi: 10.1177/1533033819825845.
This study aimed to investigate the outcomes of permanent Iodine-125 (I) radiotherapy for patients with unresectable retroperitoneal malignant tumor.
Twenty-six patients with retroperitoneal malignant tumors were implanted with I seeds under ultrasound guidance from June 2012 to June 2015. The patients were then followed up for 3 to 36 months after the implantation. During the follow-up, pain relief, control of tumor growth, over survival rate, and complications were evaluated.
Most of the patients (90%, 24/26) suffered from mild to severe pain before I seed treatment. After 1-month treatment, 16 patients had 100% pain relief, 4 patients had at least 50% pain relief, and 4 patients had no response, showing 83.3% of pain relief response. Results of computed tomography scan after 2-month I treatment indicated that 3 patients had complete remission in the tumor size, 20 patients had partial remission in tumor size, 2 patients were stable, and 1 patient had progressive disease, accounting for 88.4% response in tumor size remission. The median survival of the 26 patients was 11 months. The 1-year and 2-year overall survival rates were 46% and 27%, respectively. The median survival of the 5 patients with pancreatic cancer was 9.4 months. None of the patients had any severe complications.
I implantation could effectively relieve the pain in the patients with advanced primary or metastatic retroperitoneal malignant tumors and suppress local tumor progress.
本研究旨在探讨不可切除腹膜后恶性肿瘤患者永久性碘 125（I）放疗的疗效。
2012 年 6 月至 2015 年 6 月，26 例腹膜后恶性肿瘤患者在超声引导下植入 I 粒子。植入后对患者进行 3~36 个月的随访，评估疼痛缓解、肿瘤生长控制、总生存率及并发症情况。
大多数患者（90%，24/26）在 I 粒子治疗前存在轻至重度疼痛。治疗后 1 个月，16 例患者疼痛完全缓解，4 例患者至少 50%的疼痛缓解，4 例患者无反应，缓解率为 83.3%。2 个月后 CT 扫描结果显示，3 例患者肿瘤完全消退，20 例患者肿瘤部分消退，2 例患者肿瘤稳定，1 例患者肿瘤进展，肿瘤缓解率为 88.4%。26 例患者的中位生存期为 11 个月。1 年和 2 年总生存率分别为 46%和 27%。5 例胰腺癌患者的中位生存期为 9.4 个月。无严重并发症发生。
I 粒子植入可有效缓解晚期原发性或转移性腹膜后恶性肿瘤患者的疼痛，抑制局部肿瘤进展。
